Estrella Immunopharma, Inc. Annual Deferred Income Tax Expense (Benefit) in USD for 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Estrella Immunopharma, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate for 2022.
  • Estrella Immunopharma, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2023 was -$21.7K.
Deferred Income Tax Expense (Benefit), Annual (USD)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $29.5K Jan 1, 2022 Dec 31, 2022 10-K 2023-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.